UNSPSC 51281605: Bekanamycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15JT14C3GI chemically known as (1r,2s,3s,4r,6s)-4,6-diamino-3-((3-amino-3-deoxy-.alpha.-d-glucopyranosyl)oxy)-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranoside but generally known as bekanamycin, which bears US NIH Compound Identifier 816.

UNSPSC 51281605 Bekanamycin, a Commodity code, nominally covers a specific aminoglycoside antibiotic, but recent state and local procurement activity under this code does not reflect purchases of bekanamycin itself. Instead, the code appears to be applied inconsistently or as a catch-all within pharmaceutical procurement frameworks. The Illinois Department of Public Health used a piggyback contract through the MMCAP Infuse consortium to source Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets—neither of which are bekanamycin—from Chartwell Rx LLC in an Invitation for Bid process completed in August 2026. Seminole County, Florida issued an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, also unrelated to the code's nominal scope. These divergences suggest the code may serve as a fallback category in state and local procurement systems when a more specific pharmaceutical code is unavailable or when agencies file pharmaceutical purchases without precise commodity classification.

Recent activity under this code concentrates in Florida and Illinois, with the Illinois Department of Public Health (Springfield office) and Seminole County, Florida both active in mid-to-late 2026. The Illinois award to Chartwell Rx LLC totaled $2,999,999.11 across a 12-month initial term plus two one-year renewal options. Seminole County's procurement required quarterly deliveries to its Community Health Building in Sanford and included requirements for drug-free workplace certification, E-Verify compliance, and workers' compensation insurance, with potential FEMA funding triggering federal compliance obligations such as adherence to the Clean Air Act. Neither opportunity flagged business enterprise set-asides or domestic product preferences. The limited volume of recent opportunities and the absence of bekanamycin-specific procurement suggest this code sees minimal relevant activity and may warrant reclassification or correction by issuing agencies before committing business development resources.